New data presented at the Congress of the American Society of Hematology (ASH) on the First-line Indolent Trial (FIT) study shows nearly a 2 year improvement in progression free survival (PFS) in patients with advanced follicular lymphoma receiving Zevalin® ([90Y]-ibritumomab tiuxetan) vs, induction chemotherapy alone.1

Professor John Radford, a Consultant in Medical Oncology at the Christie Hospital in Manchester and FIT trial investigator said: "For many people with this type of lymphoma their main hope is to stay in remission for as long as possible. The FIT study shows that Zevalin, given after initial chemotherapy, produces nearly 2 additional years free of disease progression."

The [90Y]-ibritumomab tiuxetan FIT trial (First-line Indolent Trial) was a multinational, randomized Phase III trial in 414 patients, which investigated [90Y]-ibritumomab tiuxetan as first-line consolidation therapy given as a single therapeutic dose in patients with advanced (stage III or IV) follicular lymphoma who achieved at least a partial remission (PR), unconfirmed complete response (CRu) or complete remission (CR) after receiving induction chemotherapy regimens.1

The FIT study1 showed a median PFS of 37 months with [90Y]-ibritumomab tiuxetan vs. 13.5 months in the control arm (p